相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SEMA3A-mediated crosstalk between prostate cancer cells and tumor-associated macrophages promotes androgen deprivation therapy resistance
Fei Liu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020
Haibo Qiu et al.
CANCER COMMUNICATIONS (2021)
CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma
Wenhai Deng et al.
CANCER COMMUNICATIONS (2021)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
Isabella Monia Montagner et al.
CELLS (2020)
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Weimin Wang et al.
NATURE (2019)
Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin β4/FAK/SOX2/HIF-1α signaling pathway in gastric cancer
L. Gan et al.
ONCOGENE (2018)
GSCALite: a web server for gene set cancer analysis
Chun-Jie Liu et al.
BIOINFORMATICS (2018)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease
Qiang Zhang et al.
EUROPEAN UROLOGY (2018)
Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies
Paulina Nowakowska et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
Thomas Kammertoens et al.
NATURE (2017)
Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy
Dominique Bollino et al.
TRANSLATIONAL RESEARCH (2017)
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
Jae H. Park et al.
BLOOD (2016)
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
Xiuli Wang et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia
Nathan Singh et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies
E. David Crawford et al.
JOURNAL OF UROLOGY (2015)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han et al.
SCIENTIFIC REPORTS (2015)
Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000-2009
Yi Hu et al.
BMC PUBLIC HEALTH (2014)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J. Chu et al.
LEUKEMIA (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
James N. Kochenderfer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
D. V. Tassev et al.
CANCER GENE THERAPY (2012)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study
Claudia Brehm et al.
PLOS ONE (2011)
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Karl-Johan Malmberg et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Prospects for the use of NK cells in immunotherapy of human cancer
Hans-Gustaf Ljunggren et al.
NATURE REVIEWS IMMUNOLOGY (2007)
A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity
Saurabh Aggarwal et al.
CANCER RESEARCH (2006)
分享论文
